Group 1 - The A-share innovative drug concept stocks continue to rise, with Nanjing New Pharmaceutical hitting the 20% daily limit up [1] - Qizheng Pharmaceutical and Hanchang Group also reached the daily limit up [1] - Other companies such as Hite Bio, Anke Bio, Huisheng Bio, Zhendong Pharmaceutical, Tebao Bio, and Zhenbaodao saw increases of over 5% [1]

Core Viewpoint - The assisted reproductive industry has experienced significant growth, with several companies seeing substantial stock price increases, indicating a bullish market sentiment towards this sector [1] Company Performance - Joint Pharmaceutical (300966) and Lide Man (300289) both reached a 20% limit up in stock price [1] - Anke Biotechnology (300009) saw an increase of over 12% in its stock price [1] - Han Commercial Group (600774) also hit the limit up [1] - Dajia Weikang (301126) and Guangshengtang (300436) experienced notable stock price increases as well [1]

Investment Rating - The report rates the mother and baby consumption industry as "Overweight" [2][9] Core Insights - The introduction of a national childcare subsidy of 3,600 yuan per child per year, totaling up to 10,800 yuan per child, is expected to improve consumption expectations in the mother and baby sector [3] - The report highlights that despite a decline in birth rates over the past seven years, the overall mother and baby market has experienced a compound annual growth rate (CAGR) of over 15% from 2018 to 2024 due to consumption upgrades and refined parenting [3] - The report emphasizes the rise of domestic brands in the mother and baby sector, with significant market share gains and a return of industry influence to local brands [3] Summary by Sections National Childcare Subsidy - The national childcare subsidy program will start on January 1, 2025, providing cash subsidies to families with children under three years old, with a basic standard of 3,600 yuan per year [3] - Local governments are expected to introduce additional subsidies, creating a wave of local support for childbirth [3] Market Growth and Opportunities - The mother and baby market is projected to rebound due to improved policies and an anticipated increase in birth rates in 2024 [3] - Key sectors and companies recommended for investment include: - Fertility and reproductive health: Focus on companies like Jinxin Reproductive and Livzon Pharmaceutical [3] - Infant nutrition: Recommendations include China Feihe and Yili Group [3] - Baby appliances: Suggested investment in Bear Electric [3] - Apparel and home textiles: Companies like Semir and Anta are highlighted [3] - Baby care products: Brands such as Runben and New Page are recommended [3] Valuation Table - The report includes a valuation table with various companies in the mother and baby sector, indicating their stock prices, market capitalization, and profit forecasts for 2025, 2026, and 2027, along with corresponding investment ratings [4]

法律意见书 法律意见书 安徽天禾律师事务所 关于 安徽安科生物工程（集团）股份有限公司 2025 年第二次临时股东大会 之 法律意见书 安徽天禾律师事务所 关于安徽安科生物工程（集团）股份有限公司 2025 年第二次临时股东大会 之法律意见书 致：安徽安科生物工程（集团）股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以 下简称"《股东会规则》"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、法规及规范性文件的规定，安徽天 禾律师事务所（以下简称"天禾"或"本所"）指派陶闰岳、朱华耀律师出席 了安徽安科生物工程（集团）股份有限公司（以下简称"安科生物"或"公司"） 2025 年第二次临时股东大会（以下简称"本次股东大会"），对本次股东大会 的合法性进行见证并出具法律意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具 日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-038 安徽安科生物工程（集团）股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会无否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 现场会议召开时间：2025 年 7 月 28 日（星期一）上午 09:30 网络投票时间： （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 7 月 28 日 09:15 至 7 月 28 日 15:00 期间的任意时间。 2、现场会议地点：合肥市高新区海关路 K-1 安徽安科生物工程（集团）股 份有限公司（以下简称"公司"） A 座 1201 会议室 3、召开方式：本次股东大会采取现场表决与网络投票相结合的方式召开。 4、会议召集人：公司董事会 5、会议主持人：公司董事长宋礼华先生 6、会议的召集、召开与表决程序符合有关法律法规、行政法规、部门规章、 规范性文件和《公司章程》等相关规定。 ...

Group 1: Company Strategy and Goals - The overall business goal for 2025 is to achieve restorative growth and maintain stable development [3] - The company aims to enhance the sales proportion of growth hormone water injections and expand the indications for growth hormone [3] - The company plans to accelerate the production capacity of the cancer drug Trastuzumab (Ansatin) and deepen brand building and market expansion [3] Group 2: Product Development and Clinical Trials - The clinical trial for "AK2017 Injection" (recombinant human growth hormone-Fc fusion protein injection) has successfully completed Phase II enrollment, with discussions for Phase III trial already held [3] - The company is actively promoting clinical trials for interferon spray and inhalation agents, targeting respiratory infections and gynecological diseases [3] - The "AK1008 Project" (human interferon α2b spray) is in Phase II trials for treating viral infections in children [3] Group 3: Competitive Landscape - Currently, there are 5 companies producing short-acting growth hormones, and several companies are expected to launch long-acting growth hormones [4] - The market for growth hormones is competitive but the overall pricing system remains stable [4] - The strategic partnership with Weisheng Pharmaceutical aims to cover the long-acting growth hormone market and enhance the company's competitiveness in children's growth and development [7] Group 4: Innovation and Collaborations - The company is developing several innovative drugs, including "HuA21 Injection" targeting HER2, which has shown promising safety and efficacy in early trials [4] - Collaboration with Afana Company on "AFN0328 Injection" for HPV precancerous lesions is in Phase I trials, with plans for further mRNA drug development [5] - The company is also involved in CAR-T cell therapy research through its investment in Boshengji Company, which has received implicit approval for clinical trials [5] Group 5: Market Expansion and Future Plans - The company is preparing to expand its international market presence by building FDA and EU-compliant production lines and engaging with foreign distributors [8] - The exclusive agency agreement with Baoji Pharmaceutical for the innovative drug "SJ02" aims to enhance the company's product matrix in the assisted reproduction field [8] - The company anticipates that the launch of long-acting growth hormones and long-acting follicle-stimulating hormones will provide new growth points for its business [8]

Core Viewpoint - The legal opinion letter from Anhui Tianhe Law Firm confirms the compliance and legality of Anhui Anke Biotechnology (Group) Co., Ltd.'s fourth employee stock ownership plan, indicating that the company meets all necessary legal requirements for implementation [2][4][16]. Group 1: Company Qualifications - Anhui Anke Biotechnology is a legally established joint-stock company, having been approved for its initial public offering and listing on the Growth Enterprise Market in 2009 [5]. - The company is currently in good standing and does not face any legal or regulatory issues that would necessitate its termination, thus qualifying for the employee stock ownership plan [5][16]. Group 2: Legality and Compliance of the Employee Stock Ownership Plan - The employee stock ownership plan adheres to the principles of legality, voluntary participation, and risk-bearing by employees, as outlined in the relevant regulatory guidelines [6][7]. - The plan's participants will include key management and core personnel from the oncology division, with a maximum of 37 individuals, ensuring compliance with the guidelines regarding participant selection [7]. - Funding for the plan will come from employees' legal salaries and self-raised funds, aligning with regulatory requirements [7][8]. - The plan stipulates a holding period of 12 months for lock-up followed by a 60-month unlocking period, which is consistent with regulatory standards [8][9]. Group 3: Management and Governance of the Plan - The management of the employee stock ownership plan will be conducted internally, with a management committee elected by the participants, ensuring proper governance and protection of participants' rights [9][10]. - The plan allows for adjustments in participant lists based on actual contributions, maintaining flexibility in management [7][10]. Group 4: Legal Procedures and Information Disclosure - The company has completed the necessary legal procedures for the plan, including board and supervisory committee approvals, and is preparing for a shareholder meeting to finalize the plan [13][16]. - The company has fulfilled its information disclosure obligations regarding the plan, with announcements made in accordance with regulatory requirements [15][16]. Group 5: Conclusion and Future Steps - The legal opinion concludes that the company is qualified to implement the employee stock ownership plan, which complies with all relevant regulations and has undergone the necessary approval processes [16][17]. - The plan will require further approval from the shareholders' meeting, which must be passed by a majority of non-related shareholders [13][16].

Summary of Anke Bio's Conference Call Company Overview - Anke Bio focuses on biopharmaceuticals, with a strategic emphasis on traditional Chinese medicine and precision medicine, actively expanding into mRNA, ADC viruses, and cell therapy fields, particularly in the Yangtze River Delta region [2][4][31] Core Products and Development Focus - Main products include growth hormones and interferons for growth development and antiviral applications, with antibody drugs like Trastuzumab approved for market [2][5] - The company is investing heavily in biopharmaceuticals as a key growth driver, with traditional Chinese medicine as a secondary profit source, and focusing on peptides, small molecules, and cell immunotherapy to support performance growth [2][5][31] Research and Development Investment - Over the past seven years, Anke Bio has invested approximately 200 million yuan annually in R&D, accounting for about 10% of revenue, indicating a strong commitment to innovative drug development [7][8] Key R&D Areas - R&D strategy focuses on growth development, reproductive assistance, antiviral and anti-infection fields, and cancer treatment through antibodies, mRNA, CAR-T, and viral therapies [8][9] - Specific projects include in vivo CAR-T technology and mRNA platform development, with clinical trial approvals for HPV, RCV, and COVID-19 [12][13] Clinical Stage Products - Important clinical stage products include HU21 (E9), AK2017 (GHFC), AK1,008, and AK1,012, expected to enter phase III clinical trials by the end of 2025 [3][14][15] - The company plans to utilize all resources to ensure the progress of these products and expedite their market approval [15] Collaborations and Partnerships - Anke Bio is engaged in multiple collaborations, including with Baoyi for the domestic launch of the first long-acting FSH and with Weisen for long-acting growth hormone development [3][31][32] - The company has established partnerships with various academic institutions and companies to enhance its R&D capabilities and product offerings [12][29] Market Potential and Future Plans - The long-acting FSH product is expected to capture a significant market share due to its convenience over short-acting alternatives, with an estimated annual market of 1 million cycles [32] - Anke Bio aims to transition from a focus on generic drugs to innovative drug development, particularly in oncology, autoimmune diseases, cell therapy, and mRNA drugs [34] Additional Insights - The company has a highly qualified R&D team, with 40.64% holding master's degrees or higher, indicating a strong foundation for innovation [11] - Anke Bio's dual-antibody product is currently in phase I clinical trials, with plans to advance to phase II and III based on positive results [24] This summary encapsulates the key points from Anke Bio's conference call, highlighting its strategic focus, product pipeline, R&D investments, and future growth plans.

法律意见书 安徽天禾律师事务所 关于 安徽安科生物工程（集团）股份有限公司 第 4 期员工持股计划（草案） 之 法律意见书 法律意见书 安徽天禾律师事务所 关于安徽安科生物工程（集团）股份有限公司 第 4 期员工持股计划（草案） 之法律意见书 致：安徽安科生物工程（集团）股份有限公司 安徽天禾律师事务所接受安徽安科生物工程（集团）股份有限公司（下称 "安科生物"或"公司"）的委托，指派王炜、朱华耀律师（下称"本所律师"） 担任安科生物拟实施第 4 期员工持股计划（以下简称"员工持股计划"）的专 项法律顾问，根据《中华人民共和国证券法》（以下简称《证券法》）、《中 华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理委员会（以 下简称"中国证监会"）《关于上市公司实施员工持股计划试点的指导意见》 （以下简称《试点指导意见》）、《深圳证券交易所创业板上市公司自律监管 指引第 2 号——创业板上市公司规范运作》（以下简称《自律监管指引第 2 号》）等法律、行政法规、规范性文件和中国证监会的有关规定，就安科生物 第 4 期员工持股计划的相关事项出具本法律意见书。 为出具本法律意见书，本所律师谨作如下声明： 一 ...

Core Viewpoint - The strategic cooperation between Weisheng Pharmaceutical and Anke Bio aims to promote the long-acting growth hormone product, Longpei Growth Hormone, in the Chinese market, leveraging Anke's extensive experience and sales network in the biopharmaceutical sector [1][2]. Group 1: Partnership Details - Weisheng Pharmaceutical has signed a strategic cooperation framework agreement with Anke Bio, granting Anke exclusive promotion rights for Longpei Growth Hormone in specific regions of China [1]. - The collaboration will focus on the commercialization of Longpei Growth Hormone and explore broader cooperation on other target products, including localized production and marketing [1]. - Anke Bio has over 30 years of experience in biopharmaceuticals and a well-established sales network, which will facilitate Weisheng's market entry [1]. Group 2: Product Information - Longpei Growth Hormone is a new long-acting growth hormone designed to treat pediatric growth hormone deficiency (PGHD) and is expected to provide new treatment options for affected children [1]. - The product has already been approved for sale in the United States and Europe, with expectations for approval in China by 2025 and plans for localized commercial production by 2028 [1]. Group 3: Strategic Importance - Anke Bio's chairman highlighted that the collaboration will enhance their commercial layout in the pediatric growth field and redefine the growth hormone market [2]. - Weisheng's CEO emphasized the synergy between their innovative research and Anke's established sales channels, aiming to accelerate the product's market introduction and benefit a wide patient population [2].